[Open innovation and licensing in the pharmaceutical industry].
作者信息
Yamasaki Motohiro
出版信息
Nihon Yakurigaku Zasshi. 2013 Jul;142(1):28-31. doi: 10.1254/fpj.142.28.
PMID:23842225
Abstract
摘要
相似文献
1
[Open innovation and licensing in the pharmaceutical industry].
Nihon Yakurigaku Zasshi. 2013 Jul;142(1):28-31. doi: 10.1254/fpj.142.28.
2
[Open innovation: public-private partnerships in pharmaceutical R&D].
Nihon Yakurigaku Zasshi. 2013 Jul;142(1):32-8. doi: 10.1254/fpj.142.32.
3
[Change the world through business partnering - commercialization of biotechnology and open-innovation].
Nihon Yakurigaku Zasshi. 2013 May;141(5):268-74. doi: 10.1254/fpj.141.268.
4
[Requirements for the license-out of drug candidates to pharmaceutical companies].
Nihon Yakurigaku Zasshi. 2014 Apr;143(4):198-202. doi: 10.1254/fpj.143.198.
5
[Open innovation for Japanese pharmaceutical companies].
Nihon Yakurigaku Zasshi. 2013 Oct;142(4):184-9. doi: 10.1254/fpj.142.184.
6
Q&A: Bernard Munos.
Nature. 2016 May 12;533(7602):S59. doi: 10.1038/533S59a.
7
[Strategic construction of an innovative drug development pipeline by industry-academia cooperation - consortium for drug innovation in the Tokai region of Japan].
Nihon Yakurigaku Zasshi. 2014 May;143(5):254-9. doi: 10.1254/fpj.143.254.
8
[Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].
Lakartidningen. 2012;109(26-28):1280-1.
9
Open innovation: share or die..
Drug Discov Today. 2009 Nov;14(21-22):1003-5. doi: 10.1016/j.drudis.2009.09.001. Epub 2009 Sep 22.
10
Overcoming the obstacles in the pharma/biotech industry: 2008 update.
Drug News Perspect. 2009 Jan-Feb;22(1):39-51. doi: 10.1358/dnp.2009.22.1.1303817.
Zotero 插件